Ieq Capital LLC Sells 10,094 Shares of Johnson & Johnson (NYSE:JNJ)

Ieq Capital LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 7.2% in the second quarter, HoldingsChannel reports. The fund owned 130,654 shares of the company’s stock after selling 10,094 shares during the period. Ieq Capital LLC’s holdings in Johnson & Johnson were worth $19,096,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 35.9% in the second quarter. Brighton Jones LLC now owns 49,470 shares of the company’s stock worth $7,231,000 after purchasing an additional 13,078 shares during the last quarter. Burgundy Asset Management Ltd. increased its position in shares of Johnson & Johnson by 15.6% in the second quarter. Burgundy Asset Management Ltd. now owns 1,342,734 shares of the company’s stock valued at $196,254,000 after acquiring an additional 180,918 shares during the period. UP Strategic Wealth Investment Advisors LLC raised its stake in shares of Johnson & Johnson by 18.0% during the second quarter. UP Strategic Wealth Investment Advisors LLC now owns 1,532 shares of the company’s stock valued at $224,000 after acquiring an additional 234 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $2,702,000. Finally, Richardson Financial Services Inc. increased its holdings in Johnson & Johnson by 21.5% during the 2nd quarter. Richardson Financial Services Inc. now owns 497 shares of the company’s stock valued at $73,000 after purchasing an additional 88 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.8 %

NYSE JNJ opened at $164.82 on Friday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average price is $161.02 and its 200-day moving average price is $154.17. The stock has a market cap of $396.67 billion, a P/E ratio of 10.28, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Ratings Changes

Several equities research analysts have weighed in on JNJ shares. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.